Press release
With Knockout ADC Innovations, Creative Biolabs Took Center Stage at the 2024 World ADC Summit
Creative Biolabs wrapped up a successful show at the 15th Annual World ADC San Diego in the beginning of November, where its third year of participation, highlighting its dedication to the advancement of antibody-drug conjugate (ADC) technology.New York, USA - November 13, 2024 - Creative Biolabs seized the spotlight at Booth 313 by offering groundbreaking solutions across the entire ADC development spectrum, which demonstrate their unrivaled expertise and dedication to ADC research and innovation. With plans already confirmed for participation in 2025, Creative Biolabs extended an open invitation to industry peers to engage and explore partnership opportunities that drive transformative outcomes in antibody-drug conjugate discovery [https://www.creative-biolabs.com/adc/one-stop-adc-development-service.htm].
Image: https://www.getnews.info/uploads/5920b1d6b54212953051489d2b14f144.png
"At this year's World ADC, we demonstrated one-stop ADC development, a comprehensive suite that addresses the industry's evolving needs from target identification and antibody engineering to linker-payload optimization and process development," one of the delegates says, "which, as a holistic approach, enables clients to streamline their development timelines, reducing risks, and accelerating delivery from the bench to the bedside."
One of their most notable services is their bioconjugation chemistry service [https://www.creative-biolabs.com/adc/antibody-design-and-conjugation.htm], which offers advanced antibody design and conjugation options to create ADCs that are stable, specific, and effective. The meticulous design of antibody linkages and conjugation techniques is critical in crafting ADCs that effectively deliver payloads to target cells while minimizing off-target effects.
Another of Creative Biolabs' defining strengths is their pioneering work in ADC payloads [https://www.creative-biolabs.com/adc/drug-module.htm] and linker chemistry, of which the custom payload solutions cater to diverse ADC applications, leveraging a wide selection of cytotoxic agents designed for highly targeted therapeutic impact. Furthermore, Creative Biolabs' linker technology is equally critical, as stable and cleavable linkers ensure that payloads are delivered precisely to target sites without compromising efficacy or safety. This proficiency empowers clients to confront some of ADC development's most daunting challenges, like toxicity management and potency optimization.
In addition, with a specialized ADC linker module [https://www.creative-biolabs.com/adc/linker-module.htm], Creative Biolabs continues to innovate in linker-payload systems that are crucial for maximizing ADC stability in systemic circulation and enhancing therapeutic payload release at the tumor site.
"The combination of well-engineered payloads and linkers strengthens the clinical potential of ADCs, translating research breakthroughs into actionable therapies." The delegate explains.
As 2024 progresses, Creative Biolabs is poised to expand its presence at two final key events-the Scientist Solution Vendor Event - NIH 37 and the Antibody Engineering & Therapeutics (US) conference in December. Through these platforms, Creative Biolabs seeks to further its mission to collaborate, innovate, and advance antibody-based solutions.
"These events offer invaluable opportunities for in-depth exchanges with leading scientists and industry partners, solidifying our commitment to pushing the boundaries of antibody-drug conjugate technology." Says the delegate.
To learn more about Creative Biolabs' cutting-edge services in ADC discovery, bioconjugation chemistry, payload development, and linker technology, visit their website at: https://www.creative-biolabs.com/adc.
About
As ADCs continue their transformation of the oncology landscape, Creative Biolabs offers an all-encompassing ADC discovery and development service to support clients in bringing innovative therapies from the lab bench to patient bedside.
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email [http://www.universalpressrelease.com/?pr=with-knockout-adc-innovations-creative-biolabs-took-center-stage-at-the-2024-world-adc-summit]
Phone: 1-631-830-6441
Country: United States
Website: https://www.creative-biolabs.com/adc
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release With Knockout ADC Innovations, Creative Biolabs Took Center Stage at the 2024 World ADC Summit here
News-ID: 3734076 • Views: …
More Releases from Getnews
Royal Codes Founder and Designer Hartwell Sawyer Leads a New Era of Sustainable …
Eco-friendly, sustainable loungewear and athleisure crafted in ultra soft, toxinfree, OEKO-TEX certified fabrics for women who live in divine feminine energy.
Image: https://www.globalnewslines.com/uploads/2025/11/2344925ec9d7479cb3246503329899de.jpg
Royal Codes, the Bali-based slow fashion label founded and designed by Hartwell Sawyer, announces its continued growth as a prominent name among ethical Bali brands in womens activewear, loungewear, and yogawear. Built on the belief that comfort is the gateway to confidence, pleasure, and presence, Royal Codes creates elevated,…
FDA Submission for Abbreviated New Drug Application; $750 Million Market for Sui …
Image: https://www.globalnewslines.com/uploads/2025/12/1764687229.jpg
$NRXP Given a $34 Price Target in D. Boral Analyst Report
* Developing NRX-101, an FDA-Designated Investigational Breakthrough Therapy for Suicidal Treatment-Resistant Bipolar Depression and Chronic Pain.
* Designed to Help Address the Needs of Over 13 Million Americans who Seriously Consider Suicide Each Year (CDC).
* D. Boral Analyst Report on NRXP $34 Price Target.
* Abbreviated New Drug Application (ANDA) is "Substantially Complete" and Received for FDA Review. Assigned Goal Date…
BahamasMotorYachts Reveals Top Luxury Yachts for 2026 As Exumas Boom Draws US Ch …
Easy access, unmatched seclusion, and a growing selection of high-end yachts make the Bahamas the top charter choice for American travelers in 2026. BahamasMotorYachts highlights the latest fleet updates, with more power cats, superyachts, and water-focused itineraries built around privacy and exploration.
Image: https://www.globalnewslines.com/uploads/2025/11/d2d4efd411eb760fbb0c20cc4810bdca.jpg
The Bahamas has emerged as the number one yacht charter destination for American clients heading into 2026, according to BahamasMotorYachts. [https://bahamasmotoryachts.com/] The combination of direct flights from Miami,…
MyItalianCharter Names Italy the Top Destination for Classy Yacht Charters in 20 …
MyItalianCharter has named Italy the number one classy yacht charter destination for 2026, combining cultural depth, great cruising conditions, elegant settings, and a fleet of stylish, high-quality yachts. With strong demand for Amalfi and Sardinia, and rising interest in Sicily, Italy continues to set the standard for refined charter experiences.
Image: https://www.globalnewslines.com/uploads/2025/11/ce8d9365184dad566081bf9fa6073673.jpg
Italy oozes class. From the pastel cliffs of the Amalfi Coast to the quiet bays of Sardinia and the vineyards…
More Releases for ADC
ADC Market: Transforming Cancer Treatment
The global market for antibody-drug conjugates (ADCs) was valued at US$ 11.32 billion in 2023 and is expected to reach US$ 27.37 billion by 2033, growing at a compound annual growth rate (CAGR) of 9.23% from 2024 to 2033. This growth is primarily driven by the increasing prevalence of cancer and the growing demand for safe and effective treatments.
Antibody Drug Conjugates: A Growing Force in Cancer Treatment and Market Expansion
Key…
Showing Off Their ADC Game: Creative Biolabs Hits the 15th Annual World ADC Summ …
From November 4, Creative Biolabs will be back at the 15th Annual World ADC Summit in San Diego, marking its fourth year at the leading global gathering featuring innovative conjugates.
New York, USA - November 6, 2024 - Creative Biolabs invites all ADC enthusiasts, from new entrants to seasoned experts, to explore its comprehensive suite of ADC solutions and experience the latest in antibody-drug conjugate (ADC) innovation at Booth #313.
Image: https://www.getnews.info/uploads/0c59d26f78bf6dd58aafee5bc68d7d8c.jpg
"2023…
ADC Drugs For Breast Cancer Treatment
Breast cancer is the malignant tumor with the highest morbidity and mortality among women worldwide. At present, the main therapeutic methods include surgery, chemotherapy, radiotherapy, endocrine therapy and targeted therapy, etc. The development and marketing of new drugs have far-reaching significance in improving the survival of breast cancer patients and changing the pattern of breast cancer treatment.
On February 24, 2023, The NMPA approved Enhertu, an injectable drug developed jointly by…
Analog-to-Digital Converters Market by Product (Ramp ADC, Integrating ADC, Succe …
Analog-to-Digital Converters Market by Product (Ramp ADC, Integrating ADC, Successive Approximation ADC, Delta-sigma ADC, and Others (Pipelined/Flash ADC)), and Application (Consumer Electronics and Industrial) - Global Opportunity Analysis and Industry Forecast, 2017-2023
Full Report : https://www.alliedmarketresearch.com/analog-to-digital-converters-market
Increasing disposable income and technological advancements supplement the analog-to-digital converters market. However, complex design of the ADC hampers this market growth. On the other hand, encouragement in digitization of work processes by government in emerging economies,…
Global Data Converters Market Report 2017 (Analog to Digital Converter, Current …
The research report titled Global Data Converters Sales Market Report 2017 market size and forecast and overview on current market trends.
This report studies sales (consumption) of Global Data Converters Market 2017, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering
National Semiconductor
Nippon Precision Circuits Inc
Micro Analog systems
Microchip Technology.
TelCom Semiconductor, Inc
Vishay Siliconix
Texas…
ADC African Development Corporation GmbH & Co. KGaA: ADC exits shareholding in E …
ADC African Development Corporation (ADC), ISIN DE000A1E8NW9, a fast growing financial services group focusing on the frontier markets of sub-Saharan Africa, has successfully negotiated an exit for its 11.5% shareholding in Ecobank Zimbabwe for USD 5.2 million equaling approx. EUR 4.0 million. As of 30 September 2011, ADC had valued its shareholding in Ecobank Zimbabwe at EUR 1.25 million, so this transaction results in a realized profit of EUR 2.75…
